Insights from 2023 SABCS


 

SABCS 2023 Insights: "ctDNA Monitoring of ER+/HER2- High Risk Breast Cancer During Adjuvant Endocrine Therapy"

1,626 views
January 2, 2024
Comments 0
Login to view comments. Click here to Login